A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

NCT06964165 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

36

Enrollment

INDUSTRY

Sponsor class

Stopped The study stopped after meeting pre-specified futility criteria

Conditions

Ovarian Neoplasms

Interventions

DRUG: Niraparib
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

Tesaro, Inc.